Publication date: Oct 07, 2024
The success of mRNA COVID-19 vaccines has reinvigorated research and interest in mRNA-based cancer vaccines. Despite promising results in clinical trials, therapeutic mRNA-based cancer vaccines have not yet been approved for human use. These vaccines are designed to trigger tumor regression, establish enduring antitumor memory, and mitigate adverse reactions. However, challenges such as tumor-induced immunosuppression and immunoresistance significantly hinder their application. Here, we provide an overview of the recent advances of neoantigen discovery and delivery systems for mRNA vaccines, focusing on improving clinical efficacy. Additionally, we summarize the recent clinical advances involving mRNA cancer vaccines and discuss prospective strategies for overcoming immuneresistance.
| Concepts | Keywords |
|---|---|
| Covid | Cancer treatment |
| Mitigate | Delivery systems |
| Mrna | Immunotherapy |
| Tumor | mRNA vaccines |
| Vaccines | Neoantigens |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Spinosad |
| disease | MESH | tumor |
| disease | IDO | immunosuppression |